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Abstract
BACKGROUND/PURPOSE: Local and systemic control of soft tissue sarcoma (STS) remains a clinical challenge, par-
ticularly for retroperitoneal, deep truncal, or advanced extremity disease. 2′,2′-Difluoro-2′-deoxycytidine (gemcitabine)
is a potent radiosensitizer in many tumor types, but it has not been studied in human STS. The purpose of this study
was to determine the radiosensitizing potential of gemcitabine in preclinical models of human STS. MATERIALS
AND METHODS: The in vitro radiosensitizing activity of gemcitabine was assessed with clonogenic survival assay
on three human STS cell lines: SK-LMS-1 (leiomyosarcoma), SW-872 (liposarcoma), and HT-1080 (fibrosarcoma). Cell
cycle distribution was determined using dual-channel flow cytometry. The in vivo radiosensitizing activity of gemci-
tabine was assessed with subcutaneous SK-LMS-1 nude mice xenografts. Tumor-bearing mice were treated with
concurrent weekly gemcitabine and fractionated daily radiotherapy (RT) (2 Gy daily) for 3 weeks (a total dose of
30 Gy). RESULTS: The 50% inhibitory concentration (IC50) of gemcitabine for the human STS cell lines ranged from
10 to 1000 nM. Significant in vitro radiosensitization was demonstrated in all three human STS cell lines using gem-
citabine concentrations at and below the IC50. Maximal radiosensitization was associated with accumulation of cells
in early S-phase. SK-LMS-1 xenografts displayed significant tumor growth delay with combined gemcitabine and RT
compared to either treatment alone. Treatment related toxicity was greatest in the gemcitabine plus RT arm, but
remained at an acceptable level. CONCLUSIONS: Gemcitabine is a potent radiosensitizer in preclinical models of
human STS. Clinical trials combining gemcitabine and RT in human STS are warranted.
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Introduction
Soft tissue sarcomas (STSs) are a heterogeneous group of rare neo-
plasms that are thought to arise from mesenchymal tissues [1].
Whereas the majority of STS develop in the extremity, these tumors
can arise in any anatomic site, including the retroperitoneum, deep
trunk, and head and neck [2]. In sites such as the extremity, surgical
resection and radiotherapy have resulted in local control rates exceed-
ing 90% [3–5]. In contrast, in the retroperitoneum, the deep trunk,
and in advanced extremity disease, complete surgical resection with
wide margins is difficult to achieve because of anatomic constraints.
In these sites, local control is suboptimal, and local recurrence is a
major determinant of morbidity and mortality [6–9]. As such, there
is a need for novel combined modality treatment strategies to en-
hance local control in STS.
2′,2′-Difluoro-2′-deoxycytidine (dFdCyd or gemcitabine) is a de-
oxycytidine analog that has been shown to be a strong radiosensitizer
in a number of tumor types, including pancreas, head and neck squa-
mous cell carcinoma, non–small cell lung cancer, and colon carcinoma
cells [10–13]. Gemcitabine is transported into the cell followed by
phosphorylation by deoxycytidine kinase to its active di- and triphos-
phorylated forms [14,15]. Gemcitabine diphosphate inhibits ribo-
nucleotide reductase, leading to decreases in deoxynucleotide pools,
and gemcitabine triphosphate competitively incorporates into the
DNA resulting in the interruption of DNA chain elongation. Whereas
gemcitabine-mediated radiosensitization appears to be associated
with S-phase accumulation [16] and depletion of deoxyadenosine
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triphosphate (dATP) pools [10,13], the precise mechanism of this
potent radiosensitization remains unknown.
The laboratory observations of the synergism between gemcitabine
and radiation have been translated into clinical trials in pancreas
[17,18], head and neck [19], and breast cancer [20]. The purpose
of this study was to examine the radiosensitizing activity of gemcita-
bine in preclinical models of human STS. If successful, these studies
would provide a preclinical foundation for clinical trials combining
gemcitabine and radiation therapy for STS in anatomic sites where
local control rates are suboptimal.
Materials and Methods
Cell Culture
HT-1080 fibrosarcoma, SW-872 liposarcoma, and SK-LMS-1
leiomyosarcoma cells were obtained from the American Type Culture
Collection (Manassas, VA). Cells were maintained in minimum essen-
tial medium (HT-1080) or in Dulbecco’s modified Eagle’s medium
(SW-872 and SK-LMS-1) containing 10% fetal bovine serum. Cells
were passaged twice weekly and routinely tested for Mycoplasma.
Clonogenic Survival Assay
Cells were plated in 100-mm2 dishes and allowed to adhere for at
least 24 hours before treatment. Gemcitabine (Eli Lilly, Indianapolis,
IN) was dissolved in PBS and stored at −20°C until use. Irradiation
was carried out using a 250-kV orthovoltage unit (Philips, Hamburg,
Germany) at a dose rate of approximately 2 Gy/min. Dosimetry was
carried out using an ionization chamber connected to an electrometer
system that is directly traceable to a National Institute of Standards and
Technology calibration.
Cytotoxicity was assessed after a 24-hour exposure to gemcitabine.
Radiosensitization was assessed with a 24-hour exposure to gemcitabine
followed immediately by irradiation. After treatment, floating cells were
collected and added to the trypsinized adherent cells. This combination
of cells was then washed with PBS, counted on a Coulter Counter
(Hialeah, FL), and replated at clonal density. After 5 to 10 days of in-
cubation, colonies were fixed with 7:1 methanol/acetic acid and stained
with 0.5% crystal violet. Only colonies with greater than 50 cells were
counted. The plating efficiency of all three cell lines was ∼30%.
Cytotoxicity of gemcitabine was determined from the inhibitory
concentrations (ICs) derived from sigmoid curves fit to the results of
three independent experiments. Radiosensitization by gemcitabine was
determined by fitting radiation survival curves to each drug concentra-
tion using the linear quadratic equation. The mean inactivation dose
[21] (equal to the linear area under the cell survival curve) was calcu-
lated for each condition, and dose enhancement ratios (DERs) were
determined by dividing the mean inactivation dose of control cells
by the mean inactivation dose of treated cells. DERs greater than 1
indicate radiosensitization.
Cell Cycle Analysis
Bromodeoxyuridine (BrdU) flow cytometry was performed as
previously described [22]. Briefly, after a 24-hour exposure to gem-
citabine, cells were pulsed with 30 μM BrdU for 15 minutes, har-
vested, counted, fixed in ice-cold 70% ethanol, and stored at 4°C
until analysis at which time they were treated with an anti–BrdU
mouse antibody (Pharmingen, San Diego, CA), then a fluorescein
isothiocyanate–conjugated goat anti–mouse secondary antibody (Sigma,
St. Louis, MO), and finally resuspended in a solution containing
18 μg/ml propidium iodide (PI) with 40 μg/ml RNase A. Sample
sizes were approximately 1 × 106 cells, and floaters were included with
adherent cells. Trout erythrocyte nuclei (BioSure, Grass Valley, CA)
were used as an internal standard in all experiments. Samples were
analyzed by counting 10,000 events on a Becton Dickinson FACScan
flow cytometer (San Jose, CA). Cell cycle data were analyzed using
WEASEL software (version 2.3.1) from The Walter and Eliza Hall
Institute, Melbourne, Australia.
Apoptosis
Apoptosis was determined by analyzing the sub-G1 DNA content
using PI flow cytometry. Cells were harvested, washed, fixed in ice-
cold 70% ethanol, and stored at 4°C until the time of analysis when
they were washed again and resuspended in a solution containing
18 μg/ml PI and 40 μg/ml RNase. Cells were analyzed using a Becton
Dickinson FACScan flow cytometer as described above.
In Vivo Tumor Growth Assays
Exponentially growing SK-LMS-1 cells (5 × 106) were resus-
pended in PBS (200 μl) and injected subcutaneously into the flanks
of 6- to 8-week-old athymic male nude mice (Charles River Labora-
tories Inc., Wilmington, MA). Treatment commenced approximately
14 days after inoculation, once tumors reached an average volume of
150 mm3. Mice were randomized into four treatment arms (control,
gemcitabine alone, radiation alone, and gemcitabine + radiation)
with eight mice per arm. Gemcitabine was dissolved in PBS and ad-
ministered through intraperitoneal (i.p.) injection on days 1, 8, and 15,
at a dose of 150 mg/kg, given 6 hours before radiotherapy (RT). Ra-
diotherapy was administered in 2-Gy daily fractions commencing on
day 1 with five fractions per week for 3 weeks (a total dose of 30 Gy).
Mice were anesthetized with i.p. injections of ketamine (80 mg/kg)
and xylazine (4 mg/kg) and were placed prone in custom-made holders.
Cerrobend (Cerro Metal Products, Co., Bellefonte, PA) shielding was
placed over the entire mouse minus the tumor, creating a conformal treat-
ment field. After RT, mice were kept warm with heating pads until they
fully recovered from anesthesia. Animals were handled according to the
University of Michigan Laboratory Animals Maintenance Manual.
Tumor volumes (V) were estimated from the formula of a spher-
oid: V = (π/6) × D1 × (D2)
2, where D1 and D2 are the longer and
shorter perpendicular diameters, respectively. Tumor growth was ex-
pressed as the relative change in volume compared to day 1. Growth
delay of a treatment arm (GDtreatment) was defined as the time it took
the treated group to reach five times the initial volume, minus the
time it took the control group to reach the same relative volume.
The growth delay enhancement ratio (GDER) was calculated as fol-
lows: GDER = (GDGem + RT − GDGem alone)/GDRT alone. GDER
greater than 1 implies synergism between gemcitabine and RT. All
animals were euthanized when tumor volumes reached 2 cm3, and
an additional animal was sacrificed from each group on the last
day of treatment (day 19), except those of the control group which
were euthanized on day 15 because of tumor size. Tumors were har-
vested, formalin-fixed, paraffin-embedded, and stained with hema-
toxylin and eosion for histologic analysis.
Results
In Vitro Radiosensitization
The sensitivity of all three cell lines to gemcitabine alone was first
established to determine the appropriate range of doses to evaluate
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the radiosensitizing effects of gemcitabine. The 50% inhibitory con-
centration (IC50) after a 24-hour exposure to drug alone ranged
widely for all three cell lines (Table 1). The HT-1080 cells were
the most sensitive with an IC50 of 11 ± 1 nM. The SW-872 cells
were slightly more resistant with an IC50 of 45 ± 14 nM. The most
resistant cell line was SK-LMS-1 cells with an IC50 of 1070 ± 90 nM.
To evaluate the radiosensitizing properties of gemcitabine, we used
doses ranging from mildly to moderately cytotoxic (IC10–IC80). All
three cell lines demonstrated radiosensitization at doses at or below
the IC50 (Figure 1 and Table 2). Additionally, maximal radiosensitiza-
tion occurred with more cytotoxic doses of gemcitabine.
To begin to understand the mechanism of radiosensitization, we
examined the cell cycle distribution after exposure to gemcitabine.
Previous studies have demonstrated an association between S-phase
accumulation and radiosensitization [16]. In all three cell lines, after
the 24-hour treatment with gemcitabine, there was an arrest in early
S-phase, which correlated with doses of gemcitabine where radiosen-
sitization occurred (Figure 2). The most cytotoxic and radiosensitiz-
ing concentrations of gemcitabine yielded a more than two-fold
increase in accumulation of cells in early S-phase compared with
control-treated cells.
To address the potential role of apoptosis as a factor of gemcitabine-
mediated radiosensitization, cells were treated with gemcitabine and/or
radiation, and harvested immediately and 6 hours after treatment.
There was no increase in the apoptotic fraction (data not shown) as
assessed by measurement of sub-G1 content, suggesting that apoptosis
is not likely a factor involved in the radiosensitization in these three
STS cell lines.
In Vivo Radiosensitization
To evaluate in vivo radiosensitization, SK-LMS-1 nude mouse xe-
nografts were used. Of the three cell lines tested, we selected SK-
LMS-1 because they were the most resistant to gemcitabine alone
and gemcitabine-mediated radiosensitization. The dose of gemcita-
bine was determined from previous experiments (data not shown),
which found the dose of 150 mg/kg per week to be relatively non-
toxic as measured by weight loss, and produced a slight growth delay
compared with controls. The treatment schedule of weekly gemcita-
bine and daily fractionated radiation delivery was designed to mimic
a schedule that would be used in a clinical setting. The group treated
with gemcitabine and RT experienced the most significant growth
delay compared with either the RT-alone or the gemcitabine-alone
groups (Figure 3). The GDER for this combined chemoradiotherapy
group was 1.89 ± 0.45 (P = .024), indicating strong synergism be-
tween gemcitabine and RT. In fact, one xenograft in the combined
treatment group responded completely, and this mouse remains with-
out evidence of the disease 19 weeks after treatment.
Treatment-related toxicity, as measured by percent body weight loss,
was greatest in the gemcitabine + RT group, but remained at an accept-
able level (<10% loss in body weight). In this group, the maximum
weight loss (8% of initial weight) occurred on day 12 of treatment,
and all animals had returned to their starting weight 6 days after
the end of treatment (day 25). One animal in the gemcitabine-alone
Table 1. Cytotoxicity of Gemcitabine.
Cell Line Gemcitabine Dose (nM)
IC10 IC50 IC90
HT-1080 5.4 11 24
SW-872 8.2 45 240
SK-LMS-1 620 1070 1860
IC10, IC50, and IC90 indicate 10%, 50%, and 90% inhibitory concentrations.
Figure 1. Clonogenic survival of gemcitabine and radiation. HT-
1080 (A), SW-872 (B), and SK-LMS-1 (C) cells were exposed to
gemcitabine for 24 hours before irradiation. Experiments were re-
peated at least three times with representative data shown.
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treatment group died of unknown causes 5 days after the second dose
of gemcitabine.
To improve the understanding of the response to treatment, tumors
were harvested from each treatment group on the last day of treatment
(Figure 4). Control, gemcitabine-alone, and radiation-alone xenografts
remained very mitotically active despite treatment. In contrast, the
combined gemcitabine and radiation xenograft was without mitotic
figures and demonstrated enlarged cells, elongated pleomorphic nuclei,
along with significant fibrotic changes in the surrounding stroma.
These histologic findings correspond with the significant growth delay
response demonstrated in this treatment group.
Discussion
In this study, gemcitabine was found to be a potent radiosensitizer
of STS cell lines. Treatment with gemcitabine under modestly cyto-
toxic conditions radiosensitized cells in vitro. As observed in previous
studies, maximal radiosensitization was associated with accumulation
of cells in early S-phase [16]. Gemcitabine also proved to be an ex-
cellent radiation sensitizer in vivo and significantly prolonged the
tumor growth delay produced by radiation, which was associated
with histologic changes of tumor response. Given the difficulty in at-
taining local control in large extremity, truncal, and retroperitoneal
sarcomas with current therapies, these findings suggest that it may be
worthwhile to investigate the role of concurrent gemcitabine and radi-
ation therapy for these more difficult sarcoma cases.
Radiation therapy plays an important role in the treatment of STS.
Combined wide local excision and radiation therapy results in equiv-
alent rates of survival compared to radical amputation [23]. Random-
ized studies confirm that adjuvant radiation therapy improves local
control after wide excision in extremity STS [3,5]. Durable local con-
trol rates for extremity STS typically exceed 90% [3–5]; however,
local control rates are significantly worse for certain locally advanced
extremity STS cases and for STS located in unfavorable anatomic
locations, such as the retroperitoneum, pelvis, or deep trunk [6–9].
Strategies to improve the therapeutic efficacy of radiation therapy for
STS would be particularly valuable for these cases.
Gemcitabine is a deoxycytidine analog with significant systemic
activity in a variety of solid tumors, including STS. Several phase II
Table 2. In Vitro Radiosensitization of Gemcitabine.
Gemcitabine Dose (nM) Radiation Enhancement Ratio
HT-1080
5 1.22 ± 0.06
10 1.73 ± 0.09
20 2.32 ± 0.18
SW-872
15 1.27 ± 0.11
30 1.55 ± 0.36
60 2.15 ± 0.43
SK-LMS-1
250 1.06 ± 0.18
500 1.11 ± 0.17
1000 1.72 ± 0.36
Figure 2. Cell cycle arrest with gemcitabine. Cells were treated with 24 hours of gemcitabine. BrdU incorporation and PI staining were
analyzed with flow cytometry: (A) representative data for each cell line; (B) mean ± SEM for at least two independent experiments.
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clinical studies with gemcitabine as a single agent have been conducted
in patients with advanced STS [24–33]. Response rates (measured
as freedom from disease progression) in these studies have ranged
from 3% to 53%. Chemotherapy doublets coupling gemcitabine
with other agents have recently shown promise in STS. A recently
completed large randomized phase II trial comparing gemcitabine to
gemcitabine–docetaxel demonstrated superior progression-free survival
(6.2 vs 3.0 months) and overall survival (17.9 vs 11.5 months) in the
gemcitabine–docetaxel arm [26]. The role of concurrent gemcitabine–
docetaxel with radiation therapy remains to be evaluated.
In addition to its activity as a single agent, gemcitabine is known
to be a potent radiosensitizer in a variety of cell types, but the ma-
jority of data are in carcinoma models and little data exists for sarco-
ma. In vitro, gemcitabine enhances the cell-killing effects of ionizing
radiation with DERs ranging from 1.3 to 1.8 in pancreas, head and
neck squamous cell, and breast carcinoma cell lines [10–13]. These
preclinical studies provided the foundation for successful clinical trials
in pancreas, head and neck, bladder, and breast cancer [18–20,34].
Despite significant preclinical findings and numerous clinical trials,
the mechanism by which gemcitabine enhances the effect of radiation is
not completely understood. Other antimetabolites, such as 5-bromo-
2′deoxyuridine (bromodeoxyuridine) and 5-fluoro-2′-deoxyuridine
(fluorodeoxyuridine), are thought to increase cytotoxicity to radiation
by increasing the number of radiation-induced double-strand breaks
or inhibiting their repair [35,36]. However, studies have demonstrated
that neither of these mechanisms factor into gemcitabine radiosensitiza-
tion [37,38]. Other investigators have looked at the effect of p53 status.
Whereas mutant p53 cancer cells often have altered sensitivities to che-
motherapy and radiation, gemcitabine-mediated radiosensitization ap-
pears to be independent of p53 status [39,40].
Researchers from our institution have recently postulated a novel
radiosensitizing mechanism. Previous studies have shown that gem-
citabine, in its diphosphorylated form, inhibits ribonucleotide reduc-
tase [41], causing a decrease in deoxynucleotide triphosphate pools,
particularly in dATP [13]. The decrease in dATP correlates with cells
accumulating in early S-phase and radiosensitization [13,38]. Further
research has demonstrated that these gemcitabine-induced alterations
in deoxynucleotide triphosphate pools correlate with increased rates
Figure 3. Effect of gemcitabine and radiation on SK-LMS-1 xeno-
graft tumors in nude mice. SK-LMS-1 nude mouse xenografts were
randomized to four treatment arms with seven mice per arm. Mice
received weekly i.p. gemcitabine (150 mg/kg) on days 1, 8, and 15.
Radiation included 2-Gy daily fractions on days 1 to 5, 8 to 12, and
15 to 19, for a total of 30 Gy. Relative volume represents tumor vol-
ume compared with day 1 of treatment.
Figure 4. Treatment effect of gemcitabine and/or radiation. On the last day of treatment (day 19), one mouse was sacrificed from
each treatment arm. Control (A), gemcitabine-alone (B), RT-alone (C), and gemcitabine + RT (D) tumors were processed for routine
hematoxylin–eosin staining. Open arrows indicate mitotic figures, and closed arrows represent pleomorphic nuclei.
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of single-base substitutions, and it is thought that these DNA errors
contribute to the increased sensitivity to radiation [42]. This mecha-
nism is supported by the finding that cells with deficient mismatch
repair both acquire more DNA errors, and have increased sensitivity
to gemcitabine and radiation compared to cells with functional mis-
match repair [42,43].
In this study, we used three cell lines representing some of the
most common human STS histologies: fibrosarcoma, leiomyosar-
coma, and liposarcoma. These cell lines have significantly different
sensitivity to gemcitabine alone, as demonstrated by the wide range
of IC50 concentrations, yet all demonstrated radiosensitization under
moderately cytotoxic doses of gemcitabine. This is also consistent
with radiosensitization of other tumor types, where even doses of
gemcitabine significantly below the commonly used schedule were
still able to increase apparent local tumor control [19]. Taken to-
gether, the data reported in this study provide compelling evidence
that gemcitabine has similar radiosensitizing activity in sarcoma cells
to that observed in carcinoma cells. This provides a valuable preclini-
cal foundation for the clinical application of concurrent radiosensitiz-
ing gemcitabine with radiation therapy for STS.
Recently, researchers at M.D. Anderson Cancer Center have re-
ported promising preliminary results of a phase I clinical trial exam-
ining preoperative gemcitabine with radiation therapy for STSs of the
extremity or trunk [44]. Given the already high rates of local control
achieved with conventional surgery and radiation therapy for resect-
able extremity STSs, this strategy may be most useful for locally ad-
vanced or unresectable extremity or trunk sarcomas. However, the
most significant local control challenge in STSs is for the disease
located within the retroperitoneum or deep trunk [45]. Delivery of
gemcitabine with preoperative radiation therapy to retroperitoneal
sarcomas may be an attractive strategy to improve local control in
these cases. Certainly, there are significant clinical challenges in the
delivery of gemcitabine and radiotherapy to large volumes in the ab-
domen, as was demonstrated in early trials of concurrent gemcitabine
and radiation therapy for pancreatic cancer [46]. However, a number
of studies have indicated that by using conformal radiation techniques
with small treatment margins thus minimizing the volume of stomach,
duodenum, and small bowel irradiated, it is safe and feasible to treat
abdominal malignancies with concurrent gemcitabine and radiation
therapy [17,18,47]. We are currently developing a phase I clinical pro-
tocol to determine the maximal dose of gemcitabine that can be safely
administered with concurrent preoperative radiation therapy for resect-
able retroperitoneal and deep truncal STSs.
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